Efficacy and safety of etanercept in children and adolescents aged >/= 8 years with severe plaque psoriasis

Landells, I.; Paller, A. S.; Pariser, D.; Kricorian, G.; Foehl, J.; Molta, C.; Freundlich, B.

Eur J Dermatol. 2010 Feb 27; 20(3):323-8

Abstract

Etanercept, a fully human soluble tumor necrosis factor (TNF)-alpha receptor, is approved in Europe for treatment of severe plaque psoriasis in children >/= 8 years. The efficacy and safety of etanercept for this population was evaluated in a retrospective analysis of a previous study, which included 211 children (4-17 years) with psoriasis involving >/= 10% body surface area and Psoriasis Area and Severity Index (PASI) >/= 12. In this subanalysis, subjects aged 8-17 years received once-weekly subcutaneous etanercept 0.8 mg/kg (/= 8 years in this analysis and those in the original study population aged 4-17 years. In conclusion, etanercept provided significant, sustained improvement in disease severity and was well tolerated in children >/= 8 years with severe plaque psoriasis.

Read More on PubMed